Suchergebnisse - "Han, Xia"

PubPharm (53)

1

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma : ELARA trial update

enthalten in: Blood | 2024

von Dreyling, M. | Fowler, N. | Dickinson, M. | +37

2

Association between CYP2C9 and VKORC1 genetic polymorphisms and efficacy and safety of warfarin in Chinese patients

enthalten in: Pharmacogenetics and genomics | 2024

von Zhang, S. | Zhao, M. | Zhong, S. | +16

3

Safety and efficacy of tisagenlecleucel plus pembrolizumab in patients with r/r DLBCL : phase 1b PORTIA study results

enthalten in: Blood advances | 2023

von Jaeger, U. | Worel, N. | McGuirk, J. | +7

4

Unconventional treatment for an unusual cauda equina syndrome associated with nontuberculous mycobacteria after allogenic stem cell transplantation in a child with acute lymphoblastic leukemia

enthalten in: Pediatric blood & cancer | 2023

von Li, X. | Chen, H. | Han, X. | +6

5

Serum ErbB2 concentration positively correlated to the glycemic variations in newly diagnosed Type 2 diabetic patients

enthalten in: Scientific reports | 2022

von Huang, Y. | Han, X. | Chang, T. | +3

6

CYP1B1 Gene Polymorphism Based on Health Monitoring and Nursing Methods after Minimally Invasive Surgery for Lung Cancer

enthalten in: Contrast media & molecular imaging | 2022

von Liu, C. | Liu, B. | Han, X. | +1

RetractionIn: Contrast Media Mol Imaging. 2023 Oct 4;2023:9891754. - PMID 37829311

7

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia

enthalten in: Blood cancer discovery | 2022

von Pulsipher, M. | Han, X. | Maude, S. | +19

CommentIn: Blood Cancer Discov. 2022 Jan;3(1):2-4. - PMID 35019857

8

Association Between Gestational Diabetes Mellitus and the Risks of Type-Specific Cardiovascular Diseases

enthalten in: Frontiers in public health | 2022

von Mao, Y. | Hu, W. | Xia, B. | +3

9

Rutaecarpine Prevents High Glucose-Induced Endothelial Cell Senescence Through Transient Receptor Potential Vanilloid Subtype 1/ SIRT1 Pathway

enthalten in: Journal of cardiovascular pharmacology | 2022

von Xiong, Y. | Wang, H. | Yan, H. | +4

10

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET) : a multicentre, open-label, single-arm, phase 2 study

enthalten in: The Lancet. Oncology | 2021

von Schuster, S. | Tam, C. | Borchmann, P. | +26

CommentIn: Nat Rev Clin Oncol. 2021 Nov;18(11):676. - PMID 34580475

1
2
3
4
5
6
Nächster »
[6]